HomeAI · summaries
Storia in 5 fonti
Johnson & Johnson scores 1st FDA label expansion for Imaavy
Just 16 months after Johnson & Johnson scored its initial FDA app | Sixteen months after Johnson & Johnson scored its initial FDA approval for Imaavy, the pharma giant has tacked on a label expansion for the monoclonal antibody. The U.S. regulator has signed off on Imaavy to treat warm autoimmune hemolytic anemia, a rare disorder which destroys red blood cells.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark…
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- ·
benzinga.com
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.
